Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zynex Inc (ZYXI)
:ZYXI
Holding ZYXI?
Track your performance easily
Earnings Data
Report Date
Feb 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.09Last Year’s EPS
0.04Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2018
|% Change Since: -10.59%
|Next Earnings Date:Aug 02, 2018
Earnings Call Sentiment|Neutral
The earnings call presented a mixed view with substantial achievements in revenue growth, new product launches, and cash flow improvements. However, these were countered by flat overall revenue, a decline in net income and device revenue, and uncertainties in the strategic review process.Company Guidance
During the Zynex Third Quarter 2024 Earnings Conference Call, the company provided guidance indicating a robust outlook with a projected net revenue increase of approximately 9% year-over-year to reach at least $200 million, alongside a diluted earnings per share of $0.20 for 2024. The call highlighted a 13% increase in order growth for the third quarter compared to the previous year, with revenue per sales representative on an annualized basis reaching $530,000, marking a 25% improvement from Q3 2023. Zynex also reported a $10.3 million cash flow from operations year-to-date, boosting their cash balance to $37.6 million by the end of the third quarter. Looking ahead, Zynex expects fourth-quarter revenue to be at least $53.6 million, with a projected 13% increase over Q4 2023, and a diluted earnings per share of $0.09.Revenue Growth
2024 revenue expectation of $200 million is more than 50% higher than three years ago. Order growth in Q3 was up 13% year-over-year, and revenue per sales rep increased by 25% compared to Q3 2023.
FDA Clearance and Product Launches
Received FDA clearance for a new transcutaneous electrical nerve simulation device. NiCO pulse oximeter undergoing final manufacturing phase with FDA submission expected in Q4 2024.
Increased Cash Flow and Balance
Cash flow from operations in Q3 was $7.1 million, with a cash balance of $37.6 million, up 22% from Q2's balance.
Patient Monitoring Division Progress
Significant progress in the Patient Monitoring division, with FDA clearance for the second-generation blood and fluid monitor.
---
ZYXI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ZYXI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 24, 2024 | $8.59 | $9.12 | +6.17% |
| Jul 25, 2024 | $10.19 | $8.93 | -12.37% |
| Apr 30, 2024 | $10.97 | $11.77 | +7.29% |
| Feb 29, 2024 | $13.56 | $12.30 | -9.29% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Zynex Inc (ZYXI) report earnings?
Zynex Inc (ZYXI) is schdueled to report earning on Feb 27, 2025, TBA Not Confirmed.
What is Zynex Inc (ZYXI) earnings time?
Zynex Inc (ZYXI) earnings time is at Feb 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ZYXI EPS forecast?
ZYXI EPS forecast for the fiscal quarter 2024 (Q4) is 0.09.
---